Modelling Disease progression of Multiple Sclerosis in a South Wales Cohort

Emeka C Uzochukwu,Katharine E Harding,James Hrastelj,Karim L Kreft,Peter Holmans,Neil P Robertson,Emma C Tallantyre,Michael Lawton,Emeka C. Uzochukwu,Katharine E. Harding,Karim L. Kreft,Neil P. Robertson,Emma C. Tallantyre
DOI: https://doi.org/10.1159/000536427
2024-02-20
Neuroepidemiology
Abstract:Objectives: To model multiple sclerosis (MS) disease progression and compare disease trajectories by sex, age of onset, and year of diagnosis. Study Design and settings: Longitudinal EDSS scores were collected since 1985 for relapse-onset MS patients at MS clinics in South Wales and modelled using a multilevel model (MLM). The MLM adjusted for baseline covariates (sex, age of onset, year of diagnosis, and disease modifying treatments (DMTs)), and included interactions between baseline covariates and time variables. Results: The optimal model was truncated at 30 years after disease onset and excluded EDSS recorded within 3 months of relapse. As expected, older age of onset was associated with faster disease progression at 15 years (effect size (ES): 0.75; CI: 0.63, 0.86; P: <0.001) and female sex progressed more slowly at 15 years (ES: -0.43; CI: -0.68, -0.18; P: 2011) progressed more slowly than those diagnosed historically (<2006); (ES: -0.46; CI: -0.75, -0.16; P: 0.006) and (ES: -0.95; CI: -1.20, -0.70; P: <0.001), respectively. Conclusion: We present a novel model of MS outcomes, accounting for the nonlinear trajectory of MS and effects of baseline covariates, validating well-known risk factors (sex and age of onset) associated with disease progression. Also, patients diagnosed more recently progressed more slowly than those diagnosed historically.
public, environmental & occupational health,clinical neurology
What problem does this paper attempt to address?